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Abstract
Background: Although the relationship between allergic inflammation and lung carcinogenesis is not clearly
defined, several reports suggest an increased incidence of lung cancer in patients with asthma. We aimed at
determining the functional impact of allergic inflammation on chemical carcinogenesis in the lungs of mice.
Methods: Balb/c mice received single-dose urethane (1 g/kg at day 0) and two-stage ovalbumin during tumor
initiation (sensitization: days -14 and 0; challenge: daily at days 6-12), tumor progression (sensitization: days 70 and 84;
challenge: daily at days 90-96), or chronically (sensitization: days -14 and 0; challenge: daily at days 6-12 and thrice
weekly thereafter). In addition, interleukin (IL)-5 deficient and wild-type C57BL/6 mice received ten weekly urethane
injections. All mice were sacrificed after four months. Primary end-points were number, size, and histology of lung
tumors. Secondary end-points were inflammatory cells and mediators in the airspace compartment.
Results: Ovalbumin provoked acute allergic inflammation and chronic remodeling of murine airways, evident by
airspace eosinophilia, IL-5 up-regulation, and airspace enlargement. Urethane resulted in formation of atypical
alveolar hyperplasias, adenomas, and adenocarcinomas in mouse lungs. Ovalbumin-induced allergic inflammation
during tumor initiation, progression, or continuously did not impact the number, size, or histologic distribution of
urethane-induced pulmonary neoplastic lesions. In addition, genetic deficiency in IL-5 had no effect on urethane-
induced lung tumorigenesis.
Conclusions: Allergic inflammation does not impact chemical-induced carcinogenesis of the airways. These
findings suggest that not all types of airway inflammation influence lung carcinogenesis and cast doubt on the
idea of a mechanistic link between asthma and lung cancer.
Introduction
Lung cancer, especially non-small cell lung cancer
(NSCLC), presents an epidemic on the rise, accounting
for more deaths per year than the next three leading can-
cers combined [1]. Although smoking cessation is funda-
mental for lung cancer prevention, currently most lung
cancers develop in ex-smokers [2,3]. More importantly, a
significant proportion of lung cancers occur in non-smo-
kers and women [4] and there is evidence to support that
these cases are governed by a different pathobiology [5].
Hence additional strategies for lung cancer prevention
are needed to complement smoking bans, prevention,
and cessation [6]. For this to be achieved, better under-
standing of the molecular pathways that promote airway
epithelial carcinogenesis is essential.
Previous work has linked inflammation and carcino-
genesis in the gastrointestinal epithelium, and has iden-
tified the transcription factor nuclear factor (NF)-Β as
an important tumor promoter [7,8]. We and others have
proposed that, in the lungs, carcinogen-induced inflam-
mation and airway epithelial neoplasia are connected via
activation of pro-inflammatory NF-Β [9-11]. However,
experimental studies addressing the association of
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focused on innate immune responses, such as those
observed in the lungs of heavy smokers and patients
with chronic obstructive pulmonary disease [12-15].
Several epidemiologic studies have detected increased
incidence of lung cancer in non-smoking patients with
asthma [16-20]. The increased risk has been estimated
to be 1.5-3.0-fold compared to healthy non-smokers
without asthma, while some studies have reported
synergy of asthma with female gender, atopy, or poly-
morphisms in the interleukin (IL)-6 gene towards
increasing lung cancer risk [16-20]. One study also
found increased risk of dying from lung cancer among
patients with asthma [18]. Although observational evi-
dence supports an association of lung cancer with
asthma, and although both disease processes have been
extensively modeled in mice [9-11,21-26], no study to
date has functionally evaluated the effects of the allergic
adaptive immune response that characterizes asthma on
lung carcinogenesis.
In the present studies, we aimed at determining the
impact of experimental-induced allergic airway inflam-
mation on chemical-induced lung carcinogenesis in
mice. We hypothesized that either acute or chronic
allergic airway inflammation promotes lung carcinogen-
esis. We chose the most widely used models to emulate
the two conditions, the ovalbumin mouse model of
allergic respiratory inflammation and the urethane
mouse model of lung adenocarcinoma. We used the
Balb/c strain of inbred mice, which uniquely displays
susceptibility to both compounds. Studies were designed
to dissect the effects of allergic airway inflammation on
distinct time-periods of tumor initiation and promotion
in the respiratory tract. Surprisingly, we found that oval-
bumin-induced asthma does not functionally impact
urethane-induced lung carcinogenesis.
Methods
Reagents
Urethane (ethyl carbamate) was from Sigma Aldrich (St.
Louis, MO). Mouse IL-4, IL-5, IL-6, and IL-13 (detec-
tion limits: 3.0, 7.0, 5.0, and 1.5 pg/mL, respectively)
enzyme-linked immunosorbent assays (ELISA) were
from R&D (Minneapolis, MN).
Animals
Wild-type (wt) Balb/c mice were purchased from the
Hellenic Pasteur Institute (Athens, Greece) and IL-5
deficient (il5-/-) and wt (il5+/+) mice on a pure C57BL/
6 background [27] were purchased from the Jackson
Laboratory (Bar Harbor, MN). Animals were inbred at
the animal care facilities of the General Hospital Evan-
gelismos (Athens, Greece). All animal care and experi-
mental procedures were approved by the Veterinary
Administration Bureau of the Prefecture of Athens,
Greece, and conducted according to international stan-
dards (http://grants.nih.gov/grants/olaw/GuideBook.pdf).
Mice used for experiments were sex-, weight (20-25 g)-,
and age (8-10 week)-matched.
Experimental design
In a first line of experiments, Balb/c mice received a sin-
gle intraperitoneal (i.p.) injection of urethane (1 g/kg in
100 μl saline) or saline control (100 μl) on experimental
day 0. Two-stage ovalbumin treatment composed of an
initial sensitization phase [10 μg ovalbumin i.p. in
300 μl Al(OH)2] followed by inhaled challenge (10-min-
ute inhalation of aerosolized 50 mg/mL ovalbumin in
saline) or sham treatment [sensitization: 300 μli . p .A l
(OH)2; challenge: 10-minute inhalation of aerosolized
50 mg/mL ovalbumin in saline] was administered to the
same mice in three different protocols: during tumor
initiation (tumor initiation trial; sensitization: days -14
and 0; challenge: days 6, 7, 8, 9, 10, 11, and 12), tumor
progression (tumor progression trial; sensitization: days
70 and 84; challenge: days 90, 91, 92, 93, 94, 95, and
96), or continuously (chronic remodeling trial; sensitiza-
tion: days -14 and 0; challenge: days 6, 7, 8, 9, 10, 11,
and 12 and thrice weekly thereafter) (Figure 1). Mice
were sacrificed after four months. Primary end-points of
carcinogenesis were number, size, and histologic type of
lung neoplastic lesions (atypical alveolar hyperplasia
(AAH), vs adenoma and adenocarcinoma). Secondary
end-points of allergic inflammation were inflammatory
cells and mediators in bronchoalveolar lavage (BAL), as
well as morphologic evidence of airspace enlargement.
C57BL/6 il5+/+ and il5-/- mice received ten consecutive
weekly injections of i.p. urethane (1 g/kg in 100 μl
saline) [28] and were euthanized after four months.
End-point was lung carcinogenesis, as described above.
Assessment of lung carcinogenesis (primary end-point)
The lungs were explanted after transtracheal inflation
with 10% neutral buffered formalin under 25 cmH2O
pressure. Lung tumors were counted by three blinded
readers (KD, SPK, GTS) under a Zeiss Stemi DV4
stereomicroscope at ×12 magnification under both
superficial and transillumination modes and averaged
per mouse as described previously [9,28,29]. Tumor dia-
meter was determined using microcalipers under stereo-
scopic vision. Randomly selected tumors were dissected
for histologic verification of their adenomatous nature.
Excised mouse lungs were fixed in 10% neutral buffered
formalin for 24 hours. Lungs were embedded in paraffin
based on the lung base, and 5-μm-thick serial transverse
sections were cut at three levels of the lungs (apical,
median, and basal). Sections were mounted on glass
slides and stained with hematoxylin and eosin (H&E).
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type of lung lesions, including AAH, adenoma, and ade-
nocarcinoma were evaluated on the sections from each
lung by the above readers and results were averaged per
mouse.
Assessment of lung inflammation (secondary end-point)
BAL was performed using three aliquots of 1000 μl sterile
normal saline. BAL volume was not adjusted to body
mass, as all mice had similar body mass at harvest. Fluid
was combined and centrifuged at 260 g for 10 minutes to
separate cells from supernatant. Cells were resuspended
in 1 mL phosphate-buffered saline with 1% bovine serum
albumin, and total cell count was determined using a
grid hemocytometer. Cell differentials were obtained by
counting 400 cells on Wright-Giemsa-stained cytocentri-
fugal specimens. Total cell numbers in BAL were then
calculated by multiplying the percentage of each cell type
by the total number of cells. IL-4, IL-5, IL-6, and IL-13
were determined in cell-free BAL supernatants by ELISA.
Statistics
Studies were designed based on power analysis per-
formed online using freely available software (http://
www.dssresearch.com/toolkit/sscalc/size_a2.asp). We cal-
culated that, in order to detect 25% differences in the pri-
mary end-points of the study with standard deviations of
20% (tumor number and diameter), 95% confidence and
30% statistical power, eight mice per group were needed.
All values given represent mean ± standard error of
mean. To compare variables between two groups, the
Student’s t-test or the Mann-Whitney U-test were used
for normally and not normally distributed variables,
respectively. To compare variables between multiple
groups, one-way analysis of variance (ANOVA) with
Tukey’s post-hoc or Kruskal-Walis with Dunn’s post-hoc
tests were used for normally and not normally distributed
variables, respectively. All probability (P)v a l u e sa r et w o
tailed. P values < .05 were considered significant. Statisti-
cal analyses were performed and graphs were created
using Prism Version 5.0 (GraphPad, La Jolla, CA).
Results
Combined modeling of allergic inflammation and lung
cancer in Balb/c mice using ovalbumin and urethane
We initially sought to reproduce ovalbumin-induced
allergic airway inflammation and urethane-induced lung
carcinogenesis in Balb/c mice, which display sensitivity
to both models [9-11,21-26]. For this, mice received a
single i.p. dose of urethane or saline control at experi-
mental day 0 (Figure 1). After urethane, carcinogenesis
is initiated and promoted during the first four weeks,
while thereafter only progression of already established
lesions occurs [9,24,26,28]. Hence ovalbumin sensitiza-
tion and challenge were administered in three different
protocols, aiming at induction of allergic airway inflam-
mation during tumor initiation/promotion, during
tumor progression, or chronically (Figure 1). Each of the
three protocols included appropriate controls for
urethane (i.p. saline) and ovalbumin (sham sensitiza-
tion). After four months, we verified that all mice trea-
ted with urethane had lung tumors, while all mice that
received saline had no lung tumors. In addition, mice
that were sensitized and challenged with ovalbumin
Figure 1 Experimental design of studies designed to co-model allergic asthma and chemical carcinogenesis in Balb/c mice. i.p.,
intraperitoneal; n, sample size.
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control mice that received sham sensitization, except
from mice enrolled in the initiation trial, which had no
evidence of BAL eosinophilia since three months had
elapsed since ovalbumin challenge (Figure 2). There
were no differences between experimental groups in
other inflammatory cell types found in BAL, such as
macrophages and neutrophils (Table 1). We next exam-
ined IL-4, IL-5, IL-6, and IL-13 levels in BAL, since IL-
4, IL-5, and IL-13 are major mediators of allergic
inflammation [30] and IL-6 gene polymorphisms have
been associated with increased lung cancer risk in asth-
matics [19]. All mice that were sensitized/challenged
with ovalbumin consistently displayed increased BAL
IL-5 levels compared with control mice. Again, mice
enrolled in the initiation trial did not display increased
BAL IL-5, since three months had elapsed from ovalbu-
min (Figure 3). None of the other cytokines determined
(IL-4, IL-6, and IL-13) was consistently increased in
association with either ovalbumin or urethane treat-
ments. In addition to increased eosinophil numbers and
IL-5 expression in the airspace compartment, we found
additional evidence of the effectiveness of chronic oval-
bumin challenge in sensitized mice: mice that received
prolonged ovalbumin treatment developed airway remo-
deling as evidenced by macroscopic and microscopic air-
space enlargement consistent with dynamic air trapping,
a phenotype not encountered in mice that received
sham sensitization (Figure 4). The above determinations
confirmed that we could effectively model both allergic
inflammation and chemical carcinogenesis in the lungs
of our experimental mice on the Balb/c background.
Allergic airway inflammation does not impact chemical
lung carcinogenesis
We subsequently assessed lung carcinogenesis, the main
end-point of the present study in the above-described
Balb/c experimental mice that developed allergic airway
inflammation at some point during the multi-stage pro-
cess of chemical-induced lung carcinogenesis. In contrast
to our hypothesis, urethane-treated mice developed equal
numbers of lung tumors, irrespective of whether they
received ovalbumin or sham sensitization (Figure 5A).
Figure 2 Bronchoalveolar lavage (BAL) eosinophil numbers in urethane- and ovalbumin-treated Balb/c mice described in Figure 1. For
a legend to the symbols please refer to Figure 1. Dots, data points; lines, mean; bars, standard error of mean. * P < 0.05 compared with sham-
sensitized mice not treated with urethane;
### P < 0.001 compared with sham-sensitized mice treated with urethane.
Table 1 Inflammatory cells (× 10
3) in bronchoalveolar
lavage of urethane- and ovalbumin-treated Balb/c mice
described in Figure 1.
Macrophages Lymphocytes Neutrophils Eosinophils
Tumor
initiation
trial
Control 60 ± 25 4 ± 2 1 ± 1 0 ± 0
Ovalbumin 50 ± 20 3 ± 1 1 ± 0 0 ± 0
Urethane 89 ± 14 8 ± 2 1 ± 0 0 ± 0
Urethane +
ovalbumin
8 8±1 0 7±1 2±1 0±0
Tumor
progression
trial
Control 60 ± 18 7 ± 4 1 ± 0 0 ± 0
Ovalbumin 40 ± 33 7 ± 2 4 ± 3 2 ± 1*
Urethane 101 ± 14 13 ± 5 2 ± 1 0 ± 0
Urethane +
ovalbumin
49 ± 24 7 ± 2 5 ± 3 2 ± 1###
Chronic
remodeling
trial
Control 54 ± 16 7 ± 3 1 ± 1 1 ± 0
Ovalbumin 55 ± 18 8 ± 1 3 ± 1 7 ± 2*
Urethane 47 ± 12 3 ± 1 1 ± 0 0 ± 0
Urethane +
ovalbumin
84 ± 19 13 ± 6 7 ± 5 8 ± 1###
* P < 0.05 compared with sham-sensitized mice not treated with urethane;
### P < .001 compared with sham-sensitized mice treated with urethane.
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affected by the induction of acute or chronic allergic air-
way inflammation (Figure 5B). In addition, the distribu-
tion of lung neoplastic lesions between early (AAH) and
more progressed (adenoma, adenocarcinoma) histologic
types was not affected by ovalbumin-induced respiratory
inflammation. In the tumor initiation trial, sham-sensi-
tized urethane-treated mice had lung neoplastic lesions
composed of 84 ± 4% AAH, 13 ± 4% adenomas, and 3 ±
1% adenocarcinomas, while ovalbumin-sensitized
urethane-treated mice had 83 ± 3% AAH, 12 ± 2% ade-
nomas, and 5 ± 2% adenocarcinomas (P >0 . 0 5 ) ;i nt h e
tumor progression trial, sham-sensitized urethane-treated
mice had lung neoplastic lesions composed of 84 ± 7%
AAH, 10 ± 6% adenomas, and 6 ± 2% adenocarcinomas,
while ovalbumin-sensitized urethane-treated mice had
84 ± 4% AAH, 11 ± 4% adenomas, and 5 ± 2% adenocar-
cinomas (P > 0.05); finally, in the chronic remodeling
trial, sham-sensitized urethane-treated mice had lung
neoplastic lesions composed of 79 ± 3% AAH, 16 ± 2%
adenomas, and 5 ± 1% adenocarcinomas, while ovalbu-
min-sensitized urethane-treated mice had 78 ± 2% AAH,
1 5±2 %a d e n o m a s ,a n d7±1 %a d e n o c a r c i n o m a s( P >
0.05). Even mice that received ovalbumin challenge
throughout the whole time-course of chemical-induced
lung carcinogenesis (chronic remodeling trial) and devel-
oped marked allergic inflammation and airway remodel-
ing accompanied by significant air trapping, did not
exhibit evidence of enhanced tumor formation or pro-
gression. Collectively, these results indicated that allergic
inflammation does not mechanistically impact lung carci-
nogenesis in mice.
IL-5 does not affect lung carcinogenesis
To further corroborate these negative results, we used
mice with genetic deficiency in IL-5 (il5-/-), a critical
mediator of asthma which was consistently up-regulated
in the airspace compartment of mice treated with ovalbu-
min. For this, wt il5+/+ and il5-/- mice on the C57BL/6
background received ten weekly doses of urethane and
were euthanized after 4 months. il5+/+ and il5-/- mice
developed similar lung tumor numbers of equal size (Fig-
ure 6). In addition, lung tumors from il5+/+ and il5-/-
mice had a similar histologic distribution. In specific, il5
+/+ mice had lung neoplastic lesions composed of 69 ±
5% AAH, 22 ± 4% adenomas, and 9 ± 2% adenocarcino-
mas, while il5-/- mice had 75 ± 3% AAH, 19 ± 2% adeno-
mas, and 6 ± 1% adenocarcinomas (P > 0.05). Hence, in
addition to ovalbumin-induced allergic inflammation,
IL-5, a central mediator of allergic inflammation of the
airways, does not influence chemical lung carcinogenesis
induced by a prototype carcinogen.
Figure 3 Levels of interleukins (IL)-4, -5, -6, and 13, as
determined by enzyme-linked immunosorbent assay (ELISA) in
bronchoalveolar lavage (BAL) of urethane- and ovalbumin-
treated Balb/c mice described under Figure 1. For a legend to
the symbols please refer to Figure 1. Columns, mean; bars, standard
error of mean. * P < 0.05 and ** P < 0.01 compared with sham-
sensitized mice not treated with urethane;
# P < .05 and
### P < .001
compared with sham-sensitized mice treated with urethane.
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I nt h ep r e s e n ts t u d i e sw ee x p e r i m e n t a l l yt e s t e dt h e
hypothesis that allergic airway inflammation, such as
that observed in asthma, promotes lung carcinogenesis.
For this, we generated both ovalbumin-induced allergic
inflammation and urethane-induced carcinogenesis in
the lungs of Balb/c mice, sensitive to both compounds.
Allergic inflammation was induced in both an acute and
a chronic fashion and studies were designed for induc-
tion of respiratory allergy during distinct time-periods of
multi-stage lung carcinogenesis. In stark contrast to
what we anticipated based on reports of increased lung
cancer incidence in asthmatic humans, we found no evi-
dence that allergic inflammation influences chemical
carcinogenesis in the murine lung. This was the case
during both tumor initiation and tumor progression in
the respiratory tract. Even animals with long-standing
allergic airway inflammation resulting in marked struc-
tural alterations of pulmonary airways and parenchyma
did not display evidence of enhanced tumor formation
or progression. These results were furthered by studies
on mice genetically engineered to lack IL-5, a mediator
of asthma consistently up-regulated in our mice with
ovalbumin-induced allergic respiratory inflammation.
These mice did not exhibit any difference in lung tumor
induction by urethane compared to wt littermates. Col-
lectively, these studies indicate that allergic airway
inflammation does not functionally affect chemical-
induced lung carcinogenesis; that not all types of airway
inflammation influence lung carcinogenesis; and that a
mechanistic link between asthma and lung cancer may
not exist.
Most cases of lung cancer are caused by smoking [31].
In addition to genetic damage, smoking provokes
chronic inflammation in the lungs, represented by the
spectrum of illness coined chronic obstructive pulmon-
ary disease (COPD) [32]. Multiple lines of evidence
from humans, cell and mouse models support that, in
addition to the mutational stress imposed by tobacco
carcinogens, chronic inflammation caused by smoking
and/or in the context of COPD [12] can induce or pro-
mote lung cancer formation and progression [33]. In
this regard, observations of increased lung cancer inci-
dence in smokers with COPD compared with smokers
Figure 4 Macroscopic (A; Å = 10) and microscopic (B; Å = 40) images of lungs of mice enrolled in the chronic remodeling trial, as
described under Figure 1. For a legend to the symbols please refer to Figure 1. Scale bars = 500 μm.
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and duration [34,35] have been coupled with functional
studies in animal models that have identified and vali-
dated candidate molecular culprits for this link, includ-
ing NF-Β, tumor-related protein 53(TRP53, P53), and
Janus kinase (JNK) [9-11]. These lines of evidence have
established an association between innate immune
responses in the lungs and lung carcinogenesis.
However, not all cases of lung cancer are caused by
smoking. An estimated 10-15% of lung cancers is attribu-
ted to other genetic and environmental factors, such as
occupational or domestic exposure to gases, fumes, or
irritants and inherited somatic mutations or genetic
polymorphisms [36,37]. In this regard, development of
adenocarcinomas in never-smoking women in south-east
Asia has been the focus of debate [4], and there is evi-
d e n c et os u p p o r tt h a tt h e s ec a s e sa r eg o v e r n e db yad i f -
ferent pathobiology [5]. In addition, not all inflammatory
lung disorders are smoking-related. Importantly, miscel-
laneous inflammatory and fibrotic pulmonary conditions
like pulmonary fibrosis, tuberculosis, or asthma have
been reported to be associated with increased lung can-
cer incidence [36,37]. Several reports now have linked
asthma with increased lung cancer incidence [16-20], set-
ting the question of whether allergic airway inflammation
promotes carcinogenesis in the respiratory tract.
Figure 5 Parameters of lung carcinogenesis in urethane- and ovalbumin-treated Balb/c mice described under Figure 1. For a legend to
the symbols please refer to Figure 1. Dots, data points; lines, mean; bars, standard error of mean. ns, not significant; P, probability.
Figure 6 Lung carcinogenesis in wild-type (il5+/+) and interleukin (IL)-5 deficient (il5-/-) C57BL/6 mice induced by ten weekly doses of
urethane after four months latency. Dots, data points; lines, mean; bars, standard error of mean. ns, not significant; P, probability.
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eled both asthma and chemical-induced lung cancer in
mice. We used the most widely available models for this
and set power analysis-based criteria to design this work
[9-11,21-26]. Evidence for effective induction of asthma-
like allergic airway inflammation was sought: ovalbumin-
treated mice developed marked airspace eosinophilia and
IL-5 up-regulation, widely used biomarkers of asthma
[38]. In addition, mice chronically exposed to the allergen
developed structural changes reminiscent of the chronic
airway remodeling that occurs in humans with difficult-
to-treat asthma [23,38]. Despite the above efforts to dis-
cover a possible impact of experimental allergic airway
inflammation on chemical carcinogen-induced tumor
initiation or progression in the lungs of mice, our results
show the absence of such an effect. In addition, we found
that genetic deficiency in IL-5, a central mediator of
allergy and asthma, has no impact on urethane-induced
adenocarcinoma formation. This stands in contrast to
previous observations from our group on the role of the
cytokine in adenocarcinoma progression, in the forms of
malignant pleural effusion [39] and metastasis (unpub-
lished data). In fact, we have observed a marked role of
IL-5 in promoting intravenous and intrapleural tumor
progression via immunomodulatory effects on the host
response to tumor. These different results collectively
indicate that the effects of IL-5 on malignant effusion
and metastasis are specific and do not apply to more
early stages of tumor induction, and that different com-
ponents of the host immune system are involved during
the different phases of tumor formation and progression
in the respiratory tract.
Inflammation has been linked with cancer formation and
progression. However, in contrast to a generalized effect of
any type of inflammation on cancer formation, it is more
probable that specific cellular, humoral, and transcriptional
components of inflammation are involved in lung cancer
formation and progression. In the lungs, while tobacco
smoke [11] and bacterial product-induced [40] inflamma-
tion promote carcinogenesis, our study shows that allergic
inflammation characterized by specific induction of eosino-
phil and IL-5 accumulation does not enhance chemical
carcinogenesis. In this regard, while macrophages and neu-
trophils can function as potent promoters of tumor pro-
gression [41,42], eosinophils are probably mere bystanders
recruited to tumor sites of necrosis [43]. In addition, while
mediators of innate inflammation positioned within the
NF-Β pathway, such as tumor necrosis factor, promote
lung carcinogenesis [7-11,29], our studies provide evidence
that inflammatory mediators involved in other inflamma-
tory signaling pathways, such as IL-5, do not affect lung
tumor formation and progression.
The shortcomings of our studies are not to be over-
looked. We only modeled allergic airway inflammation
and chemical lung carcinogenesis using Balb/c mice, a
single allergen, and a single carcinogen. In addition, we
used the resistant C57BL/6 strain to study the role of
IL-5 in lung carcinogenesis. However, Balb/c mice
developed both allergic inflammation in response to
ovalbumin and lung tumors in response to urethane,
and should thus be an appropriate model for the study
of the interactions between the two conditions. More-
over, sufficient lung tumors were induced in C57BL/6
mice by multiple urethane doses, facilitating the study
of the role of IL-5 in lung tumor formation.
Since the original induction of urethane-induced lung
tumors in C57BL/6 mice [28], another group [44] and
we have observed increased tumor numbers in the lungs
of urethane-treated C57BL/6 mice. This phenomenon
c o u l db ea s c r i b e dt ob a c k g r o u n ds t r a i nv a r i a t i o n ,
urethane batch variation, or other unidentified reasons.
There is no evidence that C57BL/6 mice are currently
more sensitive to other commonly used carcinogens,
such as 3’-methylcholanthrene, since the original report
by Miller et al [28]. Although we and others have
observed higher tumor numbers than Miller et al.,
C57BL/6 mice are still highly resistant to urethane-
induced lung tumorigenesis.
Although negative, our study holds value in streamlin-
ing future research [45,46]. Our negative findings may
aid in focusing future basic investigations into the rela-
tionship of lung carcinogenesis with inflammation in
pertinent directions. In addition, the proposed absence
of a mechanistic impact of allergic inflammation on
lung carcinogenesis may aid towards focusing on other
possible explanations for increased lung cancer detec-
tion in patients with asthma [16-20], such as increased
medical surveillance of this patient population. Another
possible explanation for the human epidemiologic stu-
dies showing increased cancer detection in asthmatics is
non-reported (occult) smoking in self-reported non-
smokers, since these studies did not employ tobacco
exposure biomarker assessment, such as cotinine or
carboxyhemoglobin.
Conclusions
We showed herein that allergic airway inflammation of
mice that is similar to human bronchial asthma does
not affect tumor initiation or progression in the respira-
tory tract triggered by a prototype chemical carcinogen.
T h e s eu n e x p e c t e d l yn e g a t i v er e s u l t sm a ya i di nt h e
future in better understanding the increased lung cancer
risk observed in humans with asthma.
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